Abivax’s Covid-19 phase 2b/3 miR-AGE trial with ABX464 declared National Priority by French government

On Dec. 22, 2020, Abivax announced that the Companyﾒs ongoing ABX464 phase 2b/3 trial in high-risk Covid-19 patients (miR-AGE) had been declared a ﾓResearch National Priorityﾔ by the French government steering committee for therapeutic clinical trials and other research (CAPNET).

The Research National Priority designation also incentivizes clinical investigators to prioritize enrollment of their patients in these clinical trials and may provide institutional financing of these clinical studies.

Tags:

Source: Abivax
Credit:

Visit News/History Source
Transfection Has Never Been So Easy With Avalanche® Transfection Reagents for Cancer Cells, Primary Cells, And Other Difficult-To-Transfect Cells.Primary Cells, And Other Difficult-To-Transfect Cells.